Phase 3, Open-label, Multicenter, Randomized Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Subjects With Metastatic Castration-Resistant Prostate Cancer Previously Treated With Chemotherapy

This study is being done to learn more about how safe and effective the investigational immunotherapy, xaluritamig is when compared to already approved standard treatments in people with prostate cancer that has spread to other parts of the body (also known as metastatic castration-resistant prostate cancer [mCRPC]) who have already been treated with
chemotherapy.